Oxford Genetics signs major supply and licensing agreement for CRISPR engineered mammalian cell lines8 Aug 2018
Company moves away from manual processing in favour of automated, scalable platforms.
Oxford Genetics, a leader in innovative synthetic biology-based technologies for biologics discovery, development and delivery, has secured a multi-million pound contract with a leading multi-billion dollar global ecommerce provider of reagents and tools to the research and clinical community.
As part of the agreement, Oxford Genetics will leverage its high throughput automated genomic engineering platform for CRISPR modification of mammalian cell lines.
Ryan Cawood, CEO, Oxford Genetics said: “This contract highlights Oxford Genetics’ commitment to providing the highest quality cell line engineering services to its global customer base and continuing to add value to their operations. We have moved away from manual processing, which is the norm in this market, in favour of automated, scalable platforms.
“This approach means we are well positioned to deliver the large number of custom-engineered cell lines per year that the global market is forecast to need.
“We are excited about this project which will see us significantly expand our product portfolio and continue to deliver innovative products and solutions to the pharmaceutical industry.”
Headquartered in Oxford, UK, Oxford Genetics is a leading synthetic biology company dedicated to developing and delivering technologies and services to its customers that will help to change the gene editing industry. The company’s use of automation allows it to develop new and innovative solutions, the latest of which is its mammalian CRISPR cell line engineering platform.
New formulation modelling successes using ex vivo tissue
9 Oct 2018
One study uses the company's proprietary TurChub model, to evaluate the diffusion and subsequent activity of drugs in human nails.Read more
Three-way collaboration to advance gene therapy
4 Oct 2018
Partnership aims to increase the robustness and reduce costs for the manufacturing of AAV vectors.Read more
New oral treatment for metastatic melanoma receives EU authorisation
24 Sep 2018
Encorafenib in combination with binimetinib demonstrated 14.9 months median progression-free survival compared with vemurafenib monotherapy (7.3 months).Read more
Plasticell wins military contract to develop regenerative medicines for the battlefield
4 Sep 2018
Company to use its combinatorial stem cell screening platform to develop technologies for the conversion of pluripotent stem cells into platelets.Read more
New biopharmaceutical testing laboratory to open in Geneva
28 Aug 2018
SGS's expansion will enable the service provider to offer a full ICH Q6B physico-chemical characterization of biological products.Read more
Exosome isolation manufacturing and characterization
13 Aug 2018
New service to reliably and reproducibly isolate exosomes from almost any biofluid.Read more
A new era for migraine patients
6 Aug 2018
EU approves Novartis's Aimovig, a first-of-its-kind treatment specifically designed for migraine prevention.Read more
WuXi STA and Antengene sign development and manufacturing agreement
24 Jul 2018
WuXi STA chosen for its end-to-end CMC platform for new drug development.Read more
ProBioGen and Pionyr initiate 2nd immuno-oncology contract development and manufacturing project
18 Jul 2018
Parallel cell line development and analysis will allow for optimal cell line selection while compressing the development timeline.Read more
New screening company exploits the latest advances in microfluidics and 3D culture
19 Jul 2018
The ability to micro size drug-cell interactions will allow pharmaceutical and biotech companies to do 100x more testing for the same money spent as well as increasing productivity.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation